Closure of the NCBI SRA and implications for the long-term future of genomics data storage by 
The  National  Center  for  Biotechnology  Information 
(NCBI) in the US recently announced that, as a result of 
budgetary constraints, it would no longer be accepting 
submissions to its Sequence Read Archive (SRA) and that 
over the course of the next year or so it would slowly 
phase  out  support  for  this  database  (http://www.ncbi.
nlm.nih.gov/sra). There seems to be a certain amount of 
confusion  in  the  community  about  what  effect  this 
decision will have. At Genome Biology we feel that the 
free availability of data is an important concept for science, 
so we asked the views of various interested people on what 
the  short-term  implications  of  this  announcement  will 
be, and also how they envisaged the future of data storage 
in the long term. These people include those involved in 
the running of the databases (David Lipman (DL) from 
the NCBI and Paul Flicek (PF) from the European Bio-
informatics Institute (EBI)) and users of the data stored 
in the database as well as data producers (Steven Salzberg 
(SS)  from  the  University  of  Maryland,  Mark  Gerstein 
(MG) from Yale University and Rob Knight (RK) from the 
University of Colorado).
1. Why did the SRA close? How widely used by the 
community was it?
DL:  NCBI  was  facing  budgetary  constraints  and 
presented a range of options to the National Institutes of 
Health  (NIH)  leadership,  who  chose  to  phase  out  the 
SRA along with other resources. One factor in making 
the  determination  was  the  understanding  that  because 
the raw sequence data within the SRA are processed into 
derived  forms  in  order  to  answer  the  underlying  bio-
logical questions, as methods mature, the SRA was seen 
as a transitional resource. The SRA primarily has been 
used by a relatively small community of project analysts 
and  researchers  working  on  methods  develop  ment  in 
genome scale research projects.
PF: The SRA isn’t closing. It started as a joint venture 
between the NCBI and the EBI, so the NCBI ceasing to 
accept submissions doesn’t meant that the SRA is closing, 
merely changing and the European Nucleotide Archive 
(ENA)  at  EMBL-EBI  will  remain.  The  NCBI’s  decision 
was based on budgetary constraints. It should be noted 
that most people don’t realize that storage space is only a 
minor fraction of the budget of the database; the bulk of 
the  cost  is  associated  with  the  staff  who  maintain  the 
database, process the submissions, develop the software 
and so on.
SS: From the outside, it appears that the SRA is closing 
because of NIH budgetary considerations. One problem 
is  that  the  amount  of  sequence  being  generated  is 
growing  at  an  extraordinary  rate,  probably  faster  than 
increases to the budget. My group uses the SRA a lot. 
Due to the nature of our work, we rely on it maybe more 
than  others.  We  download  data  reasonably  frequently, 
but because of the size of the datasets we try not to do it 
too often.
RK: The SRA was widely disliked by a lot of users, in 
particular because it was hard to get data. Partly that 
was because of poor standards for metadata associated 
with  the  data  entries.  This  makes  it  hard  to  find  the 
samples  you  were  looking  for.  It  wasn’t  set  up  for 
projects that were generating many samples at a time, 
and multiplexing with barcoded samples was also not 
supported.  This  made  it  particularly  unsuitable  for 
metagenomics  data.  It’s  possible  that  other 
communities, such as the cancer genomics community, 
had better experiences.
MG: I don’t really know the details. I’ve heard some 
speculation that it might be a bit of brink  manship.
2. What are the alternatives now to the SRA?
DL: Our partners in Europe at the EBI and in Japan at 
DDBJ will continue to archive raw sequence data in their 
SRA repositories.
PF: Well, the ENA [via the EBI].
SS:  GEO  can  be  used  for  RNA-seq  data.  For  whole 
genome sequencing, the alternatives are a little unclear, 
but  it  may  be  that  groups  that  are  generating  the 
sequences will have to store the data themselves. Funding 
agencies  may  have  to  consider  funding  not  just  the 
sequencing projects but storage of the resulting data too. © 2010 BioMed Central Ltd
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community-led  databases  such  as  the  Metagenomics 
Analysis Server (MG-RAST, http://metagenomics.anl.gov/), 
Integrated Microbial Genomes/Metagenomics (IMG/M, 
http://img.jgi.doe.gov/cgi-bin/m/main.cgi),  Community 
Cyberinfrastructure  for  Advanced  Microbial  Ecology 
Research and Analysis (CAMERA, http://camera.calit2.
net/) and Visualization and Analysis of Microbial Popu-
lation  Structures  (VAMPS,  http://vamps.mbl.edu/). 
Other communities probably have their own databases.
MG:  We’ve  heard  that  the  ENA  will  remain  open. 
We’ve also heard that the NCBI will continue to accept 
submissions from some of the large established projects, 
such as ENCODE, at least in the near future.
3. Will other repositories/alternatives provide a 
suitable replacement for archiving short read data, 
now and in the future?
DL: The NIH institutes are investigating alternatives to 
the SRA for archiving sequence read data for its grantees.
PF:  The  EBI  will  continue  to  accept  submissions.  In 
order to cope with the increase in submission numbers, 
we’re  working  on  extending  ENA’s  ‘ecosystem’  model 
with various groups or organizations acting as brokers, or 
a  single  submission  pipeline,  for  data  submission.  The 
EBI is working on implementing ‘reference-based com-
pres  sion’, which will drastically reduce the amount of disk 
space per stored sequenced base and hence the cost of 
that storage. Some communities haven’t been well served 
by  the  way  the  SRA  was  organized,  with  the  meta-
genomics community being a good example. The EBI is 
working on ways to address that.
SS: If the ENA’s SRA is going to be stable, that would be 
a good alternative. The 1000 Genomes project has been 
investigating  using  the  cloud.  One  alternative  might 
potentially be, rather than keeping the sequence data, as 
sequencing is getting so cheap, to instead just store the 
DNA  and  re-sequence  it  as  needed.  Certainly  for 
bacterial genomes, that’s currently a feasible option. This 
also avoids the problem of changing formats for digital 
storage. DNA won’t change, but computer disks will.
RK: The EBI’s SRA has a better data submission pipe-
line than NCBI’s, and I understand the EBI is keen to 
involve  communities  to  ensure  the  database  is  better 
tailored  to  individuals’  needs.  In  the  long  term  it  is 
probably  better  to  just  store  the  samples  and  then 
resequence them with improved technology.
MG:  It’s  extremely  important  that  there  is  a  proper 
archive to put things in. The European archive could be a 
good place to store data, but it seems to me that it is not 
good for the US not to have a national archive. It seems 
strange to me that we would have a situation where the 
US  is  paying  to  generate  all  these  data  -  probably  the 
majority  of  genomics  data  is  coming  from  the  US  at 
present - but where it’s not prepared to meet the cost of 
archiving the data.
4. Should we store short reads at all?
DL: As the performance of next-generation sequencing 
machines continues to improve in terms of speed, cost, 
accuracy,  and  length,  and  as  computational  processing 
continues to improve, the need to access the underlying 
reads decreases. This will vary depending on the appli-
cation (such as RNA-seq, metagenomics, cancer genomics, 
and so on). For all of these applications, however, there 
needs to be more attention focused on the specifications/
guidelines/requirements of the derived data, which will 
become  the  primary  object  of  study,  exchange,  and 
archiving.
PF: As with any archiving project, one needs to con-
sider the cost of storage relative to the potential future 
reuse. In the course of the 1000 Genomes project, for 
example, the raw sequencing reads have been realigned 
and  reanalysed  many  times.  Different  short  read  types 
will have different requirements for storage. For instance, 
RNA-seq  and  ChIP-seq  datasets  probably  require  less 
information to be stored than genome sequences where 
the goal is identifying variants.
SS: It’s very hard to get researchers to agree to not keep 
their raw reads! Even if it’s not a case of deleting the data, 
but just moving it to some sort of less accessible back-up 
storage. We definitely need to store the short reads in the 
short term. For instance, if you’re comparing differences 
between two genome assemblies you need to be able to 
go back to the raw reads to check if the differences are 
real or if it’s just an assembly problem. It’s also important 
for other groups to be able to verify or replicate reported 
results. Perhaps data will be stored for a few years in a 
readily available format, then moved to back-up storage, 
before finally being deleted.
RK: If there is a good chance that the data are going to 
be  used  by  others,  then  yes,  there  is  a  good  case  for 
storing them. Just storing the raw data for the sake of it, 
however, is probably not worth it. Higher-level data can 
sometimes be more useful.
MG: I strongly feel that the data should be archived. A 
lot of the genomics community would feel that generating 
data just to be thrown away would be anathema.
5. What is going to happen to the back catalog of 
data currently stored in the NCBI SRA?
DL: NCBI believes that it has the resources to support a 
static, unmonitored public archive for 12 months. After 
that, NCBI will re-evaluate. We can also transfer existing 
data  to  new  providers  by  tape  or  disk.  All  publicly 
available data are accessible through EBI and DDBJ.
PF: It will continue to be available from the EBI. The 
data are currently mirrored.
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we’ll be able to access them in future.
RK: I don’t know in general, but the subset of the data 
useful for metagenomics is rapidly finding its way into 
other resources (for example, we have already deposited 
all our SRA data into MG-RAST).
MG: My impression is that they’re certainly not going 
to delete all of that.
6. How will other data repositories fare in the 
future given the data deluge that is occurring? Will 
central repositories become a thing of the past?
DL:  For  most  of  the  assembled  sequence  entries  in 
GenBank,  including  the  reference  human  genome 
sequence, the underlying sequence reads are not readily 
available. The phasing out of the SRA, while somewhat 
accelerated because of budgetary constraints, should not 
be  unexpected  given  the  evolution  of  next-generation 
sequencing applications. While the growth in the volume 
of data derived from next-generation sequencing will be 
steep,  this  can  certainly  be  accommodated  by  the 
approaches  the  centralized  databases  have  taken  for 
several  decades.  So  we  believe  we’ll  continue  to  see  a 
mixture of distributed and centralized repositories in the 
biomedical and life sciences.
PF: I think the community wants something relatively 
simple. They want somewhere to store their data, and to 
be able to access it easily. There will always be a role for 
central repositories. The storage costs are similar whether 
data are stored centrally or in dispersed locations, but 
there  are  economies  of  scale  involved  in  handling  the 
data associated with a central repository. It is also more 
convenient  for  users  such  as  journals  and  other 
researchers to have a central point to access the data.
SS: Central repositories are far more efficient. It’s not 
clear if governments will be prepared to fund them, but 
they should do because it’s cheaper. It would be a mess to 
have  different  data  in  different  places,  perhaps  with 
duplications, with each database having different formats 
or policies for data access, different reliabilities and so on. 
GenBank, ENA and DDBJ have been hugely valuable for 
the  community,  not  least  because  they  have  had  strict 
policies for free availability of the data.
RK: In some ways a central repository doesn’t make 
sense. It is hard to envisage a situation where a user will 
want  to  access  both  cancer  genomics  data  and  meta-
genomics data, for instance. The economies of scale with 
centralized databases are in some sense false. It is cheaper 
to have user-friendly resources tailored to the needs of 
the community they’re serving. It costs money for users 
to spend time trying to work out how to access the data. 
It is likely that any central repository will run into similar 
problems to the NCBI SRA.
MG: Due to the huge size of the files, uploading and 
downloading data from a central repository is not easy. 
The model of a central archive may need to be revisited 
and we may see in the future an increased use of cloud 
computing resources.
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